Effect of curcumin on head & neck cancer patients receiving chemoradiatio
Phase 3
- Registration Number
- CTRI/2023/02/050028
- Lead Sponsor
- one
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients with histopathologically proven head and neck cancers receiving CRT
Karnofsky performance staus [KPS] > 70 %
No prior chemotherapy or radiotherapy
Exclusion Criteria
Patients who refuse to give consent
General medical conditions preventing combined modality treatment
Pregnancy or breastfeeding
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To see overall response rate by using curcumin as a radiosensitizer in head and neck cancer patientsTimepoint: After 6 weeks of completion of chemoradiation <br/ ><br> <br/ ><br>
- Secondary Outcome Measures
Name Time Method To assess toxicity <br/ ><br>Timepoint: weekly during Radiotherapy <br/ ><br> <br/ ><br>